JHL Biotech focuses on developing and manufacturing affordable biologic medicines, with an emphasis on biosimilars, bioengineering and innovative manufacturing solutions. The company provides process development and cGMP manufacturing services and helps global partners access the China market. JHL's pipeline includes proprietary biosimilar compounds and a pre-clinical novel therapeutic portfolio. The company plans to use new funding to continue biosimilar programs through clinical trials, construct a fill-finish facility at its Wuhan commercial manufacturing plant, expand its pre-clinical novel therapeutic portfolio, and support working capital. With the Series C proceeds, JHL has secured capital necessary to complete full development and BLA filing of at least two of its proprietary biosimilar compounds. Founded in 2012 and led by President and CEO Racho Jordanov, the company is based in Hsinchu. Founded in December 2012 and led by President and CEO Racho Jordanov, JHL Biotech focuses on bioengineering and product development under current Good Manufacturing Practices (cGMP). The company has five biosimilar programs and one new molecular entity in development, with an emphasis on biosimilar monoclonal antibodies. It completed construction of a clinical manufacturing facility in Hsinchu, Taiwan in December 2013 and has formed partnerships with domestic academic and government institutions as well as regional and global biotech and pharmaceutical companies. JHL plans to submit its first clinical trial and investigational new drug (IND) applications in 2015. Financially, it closed a $35M Series B to fund development of its biosimilar mAb pipeline, accelerate IND filings, support facility expansion in Taiwan, and acquire equipment for a commercial manufacturing facility in Wuhan, China expected to be completed by 2014 year-end. The financing is intended to support both R&D progress and commercial manufacturing build-out.

Total raised

$81M

Funding rounds

2

Latest round

Series C

Latest activity

May 2015